PPH VanEck Pharmaceutical ETF Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
18:33
Aug 05
Sarah Ketterer CEO and Fundamental Portfolio Manager, Causeway Capital Man… Bloomberg Markets
Pharma offers AI upside and defense.
Pharmaceuticals are an underappreciated AI beneficiary with yield and strong balance sheets, offering a defensive play at a time when AI-driven drug discovery could compress development timelines and enhance productivity significantly.
PPH 1ST
HIGH
21:29
Jan 09
Richard Saperstein Founding Principal and CIO of Hightower Treasury Partners CNBC
Recently added drug stocks to portfolio.
He says they recently added some drug stocks, though he does not name specific companies or give a detailed rationale.
PPH 1ST
LOW
00:28
Jan 06
Jim Cramer Host, Mad Money CNBC
Drug stocks on sale today
Cramer said drug stocks were on sale today and that he likes to watch declines to find good entry points. He used the group's selloff as the setup before naming his preferred names.
PPH 1ST
MED
Log in to see ideas

About PPH Investor Commentary

Across the available history and selected sources, Buzzberg tracks PPH (VanEck Pharmaceutical ETF) across 3 sources: 4 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 4 total trade ideas tracked. Latest voices: Sarah Ketterer, Richard Saperstein, Jim Cramer.